Considering OS, in patients with high PD-L1 expression (immune cell ≥25% or tumor cell ≥50%), Durva-mono and Durva-Treme were not superior to EXTREME; however, Durva-mono and EXTREME were comparable. This evidence concerns the gene CD274 and neoplasm.